Industry Focus
Healthcare: Are These Two Biotech Stocks Too Risky To Buy?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:18:13
- Mas informaciones
Informações:
Sinopsis
MannKind and Orexigen: two companies with big promise, but can they deliver on profit? Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the risks facing these biotech stocks.
